<DOC>
	<DOCNO>NCT02187484</DOCNO>
	<brief_summary>The antihypertensive effect , safety usefulness treatment BIBR 277 capsule evaluate hypertensive patient nephropathy</brief_summary>
	<brief_title>BIBR 277 Capsules Hypertensive Patients With Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Condition : Either follow criterion satisfied laboratory test : Presence renal parenchymal disorder chronic glomerulonephritis confirm ( serum creatinine &lt; 3.0 mg/dL ) Presence renal function disorder ( serum creatinine ≥ 1.5 mg/dL &lt; 3.0 mg/dL ) Age : ≥ 20 year Sex : Either male female Patient status : Either outpatient inpatient . However , patient status remain unchanged throughout study period Blood pressure ( BP ) : [ Outpatients ] The last 2 measurement sit BP least 3 take observation period ( 2 4 week ) stable mean two measurement ≥160 mmHg systolic BP ( SBP ) ≥95 mmHg diastolic BP ( DBP ) [ Inpatients ] The last 2 measurement supine BP take observation period ( 1 week ) stable mean 2 measurement ≥ 150 mmHg SBP ≥ 90 mmHg DBP Renovascular hypertension Undergoing haemodialysis Severe hypertension ( Diastolic BP ≥ 120 mmHg ) Severe heart failure , angina pectoris , history myocardial infarction Atrioventricular conduction disturbance ( degree II III ) , atrial fibrillation , serious arrhythmia Symptoms cerebrovascular disorder Serious hepatic dysfunction Uncontrolled diabetes Peptic ulcer History hypersensitivity drug Hyperkalaemia Undergoing treatment digitalis preparation Pregnant , breast feeding , possibly pregnant plan become pregnant study Otherwise judge ineligible investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>